Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to demonstrate that at least one of the two doses of Berodual® (50 µg fenoterol
hydrobromide/20 µg ipratropium bromide and 25 µg fenoterol hydrobromide/10 µg ipratropium
bromide, 1 puff q.i.d.) administered via Respimat® gives a bronchodilator response which is
not inferior to that obtained from one dose of Berodual® (50 µg fenoterol hydrobromide/21 µg
ipratropium bromide, 2 puffs q.i.d.) administered via MDI and that the safety profile is at
least as good in asthma patients treated for 12 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Fenoterol Fenoterol, ipratropium drug combination Ipratropium